<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Physiotherapy, Balneology and Rehabilitation</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Physiotherapy, Balneology and Rehabilitation</journal-title><trans-title-group xml:lang="ru"><trans-title>Физиотерапия, бальнеология и реабилитация</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1681-3456</issn><issn publication-format="electronic">2413-2969</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">634197</article-id><article-id pub-id-type="doi">10.17816/rjpbr634197</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original studies</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Effect of systemic ozone therapy added to pharmacological treatment on brain-derived neurotrophic factor (BDNF) and cognitive status in post-COVID patients</article-title><trans-title-group xml:lang="ru"><trans-title>Влияние системной озонотерапии в дополнение к фармакологическому лечению на нейротрофический фактор мозга и когнитивный статус пациентов с постковидным синдромом</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title/></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-4791-8674</contrib-id><contrib-id contrib-id-type="spin">4396-3438</contrib-id><name-alternatives><name xml:lang="en"><surname>Soldatenko</surname><given-names>Alexander A.</given-names></name><name xml:lang="ru"><surname>Солдатенко</surname><given-names>Александр Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>alex.psycho.na@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0944-3591</contrib-id><contrib-id contrib-id-type="spin">3452-8033</contrib-id><name-alternatives><name xml:lang="en"><surname>Gumenyuk</surname><given-names>Lesya N.</given-names></name><name xml:lang="ru"><surname>Гуменюк</surname><given-names>Леся Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>lesya_gymenyuk@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9057-1530</contrib-id><contrib-id contrib-id-type="spin">2478-2563</contrib-id><name-alternatives><name xml:lang="en"><surname>Bobrik</surname><given-names>Yuri V.</given-names></name><name xml:lang="ru"><surname>Бобрик</surname><given-names>Юрий Валерьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>yura.bobrik@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Avicenna Multidisciplinary Clinical and Diagnostic Centre</institution></aff><aff><institution xml:lang="ru">Многопрофильный клинико-диагностический центр «Авиценна»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Order of the Red Banner of Labor of the Medical Institute named after S.I. Georgievsky of the V.I. Vernadsky Crimean Federal University</institution></aff><aff><institution xml:lang="ru">Ордена Трудового Красного Знамени Медицинский институт имени С.И. Георгиевского ФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского»</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-11-04" publication-format="electronic"><day>04</day><month>11</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-02-20" publication-format="electronic"><day>20</day><month>02</month><year>2024</year></pub-date><volume>23</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>57</fpage><lpage>67</lpage><history><date date-type="received" iso-8601-date="2024-07-10"><day>10</day><month>07</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-08-19"><day>19</day><month>08</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2024,</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder></permissions><self-uri xlink:href="https://rjpbr.com/1681-3456/article/view/634197">https://rjpbr.com/1681-3456/article/view/634197</self-uri><abstract xml:lang="en"><p><bold><italic>BACKGROUND: </italic></bold>Treatment is required for post-COVID cognitive impairment associated with functional limitations, reduced work capacity, and significant deterioration in quality of life. Pharmacological treatment is ineffective. In this context, physical therapy, especially systemic ozone therapy with potential neuroprotective effects, appears promising.</p> <p><bold><italic>AIM:</italic></bold><italic> </italic>The aim of the study was to evaluate the effect of systemic ozone therapy added to pharmacological treatment on plasma brain-derived neurotrophic factor (BDNF) levels and cognitive status in patients with post-COVID cognitive impairment.</p> <p><bold><italic>MATERIALS AND METHODS:</italic></bold><italic> </italic>A total of 140 patients aged 18-45 years with post-COVID asthenic syndrome were evaluated and treated. They were randomized into two groups: an experimental group with 70 subjects who received systemic ozone therapy in addition to pharmacological treatment and the comparator group with 70 subjects who received pharmacological treatment only. Pre- and post-treatment outcomes were assessed using plasma BDNF levels and the Montreal Cognitive Assessment (MoCa) score.</p> <p><bold><italic>RESULTS:</italic></bold><italic> </italic>Statistically significant differences in BDNF levels (<italic>р</italic>=0.034) and MoCa scores (<italic>р</italic>=0.002) were found between the compared groups at the end of therapy (day 30). In our study, adding systemic ozone therapy to pharmacological treatment in patients with post-COVID cognitive impairment normalized BDNF levels and completely improved clinical manifestations of cognitive impairment in 95% of subjects.</p> <p><bold><italic>CONCLUSION: </italic></bold>Therefore, systemic ozone therapy can be considered as one of the effective and pathogenetically proven strategies for comprehensive treatment of patients with post-COVID cognitive impairment in the outpatient setting.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Постковидные когнитивные нарушения, ассоциированные с функциональными ограничениями, снижением трудоспособности и значительным ухудшением качества жизни, требуют коррекции. Фармакологическое лечение недостаточно эффективно. В связи с этим перспективным представляется использование физиотерапевтических методов, в частности системной озонотерапии, обладающей потенциальным нейропротекторным действием.</p> <p><bold>Цель исследования </bold>― изучить влияние системной озонотерапии, применяемой в дополнение к фармакологическому лечению, на показатели мозгового нейротрофического фактора (BDNF) в плазме крови и когнитивный статус пациентов с постковидными когнитивными нарушениями.</p> <p><bold>Материалы и методы.</bold> Обследовано и пролечено 140 пациентов в возрасте от 18 до 45 лет с постковидным астеническим синдромом, рандомизированных на две группы. Пациенты основной группы (<italic>n</italic>=70) получали системную озонотерапию дополнительно к фармакологическому лечению, в группе сравнения (<italic>n</italic>=70) ― только фармакологическое лечение. Результаты до и после лечения оценивали по показателям мозгового нейротрофического фактора в плазме крови и Монреальской шкалы оценки когнитивных функций (MoCa).</p> <p><bold>Результаты. </bold>По завершении терапии (на 30-й день) получены статистически значимые различия между сравниваемыми группами по показателям нейротрофического фактора мозга (<italic>р</italic>=0,034) и шкалы оценки MoCa (<italic>р</italic>=0,002). Добавление системной озонотерапии к фармакологическому лечению пациентов с постковидными когнитивными нарушениями в нашем исследовании позволило добиться у них нормализации уровня нейротрофического фактора мозга, а также полной редукции клинических проявлений когнитивных нарушений в 95% случаев.</p> <p><bold>Заключение. </bold>Применение системной озонотерапии может рассматриваться в качестве одной из эффективных и патогенетически обоснованных стратегий комплексного лечения пациентов с постковидными когнитивными нарушениями в амбулаторных условиях.</p></trans-abstract><trans-abstract xml:lang="zh"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>post-COVID cognitive impairment</kwd><kwd>systemic ozone therapy</kwd><kwd>brain-derived neurotrophic factor</kwd><kwd>BDNF</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>постковидные когнитивные нарушения</kwd><kwd>системная озонотерапия</kwd><kwd>нейротрофический фактор мозга</kwd><kwd>BDNF</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Buttery S, Philip KE, Williams P, et al. Patient symptoms and experience following COVID-19: Results from a UK-wide survey. BMJ Open Respir Res. 2021;8(1):e001075. doi: 10.1136/bmjresp-2021-001075</mixed-citation><mixed-citation xml:lang="ru">Buttery S., Philip K.E., Williams P., et al. Patient symptoms and experience following COVID-19: Results from a UK-wide survey // BMJ Open Respir Res. 2021. Vol. 8, N 1. P. e001075. doi: 10.1136/bmjresp-2021-001075</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Chen C, Haupert SR, Zimmermann L, et al. Global prevalence of post COVID-19 condition or long COVID: A meta-analysis and systematic review. J Infect Dis. 2022;226(9):1593–1607. doi: 10.1093/infdis/jiac136</mixed-citation><mixed-citation xml:lang="ru">Chen C., Haupert S.R., Zimmermann L., et al. Global prevalence of post COVID-19 condition or long COVID: A meta-analysis and systematic review // J Infect Dis. 2022. Vol. 226, N 9. P. 1593–1607. doi: 10.1093/infdis/jiac136</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Seang S, Itani O, Monsel G, et al. Long COVID-19 symptoms: Clinical characteristics andrecovery rate among non-severe outpatients over a six-month follow-up. Infect Dis Now. 2022; 52(3):165–169. EDN: VYRYWF doi: 10.1016/j.idnow.2022.02.005</mixed-citation><mixed-citation xml:lang="ru">Seang S., Itani O., Monsel G., et al. Long COVID-19 symptoms: Clinical characteristics andrecovery rate among non-severe outpatients over a six-month follow-up // Infect Dis Now. 2022. Vol. 52, N 3. P. 165–169. EDN: VYRYWF doi: 10.1016/j.idnow.2022.02.005</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 Months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019</mixed-citation><mixed-citation xml:lang="ru">Davis H.E., Assaf G.S., McCorkell L., et al. Characterizing long COVID in an international cohort: 7 Months of symptoms and their impact // EClinicalMedicine. 2021. Vol. 38. P. 101019. doi: 10.1016/j.eclinm.2021.101019</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Boutou AK, Asimakos A, Kortianou E, et al. Long COVID-19 pulmonary sequelae and management considerations. J Personal. Med. 2021;11(9):838. doi: 10.3390/jpm11090838</mixed-citation><mixed-citation xml:lang="ru">Boutou A.K., Asimakos A., Kortianou E., et al. Long COVID-19 pulmonary sequelae and management considerations // J Personal. Med. 2021. Vol. 11, N 9. P. 838. doi: 10.3390/jpm11090838</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Zaharov DV, Burjak JV. Postcognitive cognitive disorders. Current view of the problem, pathogenesis and therapy. Obozrenie psihiatrii i medicinskoj psihologii imeni V.M. Behtereva = Bekhterev review of psychiarty and medical psychology. 2021;55(4):97–105. EDN: QSADXH. doi: 10.31363/2313-7053-2021-57-4-97-105</mixed-citation><mixed-citation xml:lang="ru">Захаров Д.В., Буряк Ю.В. Постковидные когнитивные расстройства. Современный взгляд на проблему, патогенез и терапию // Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2021. Т. 55, № 4. С. 97–105. EDN: QSADXH. doi: 10.31363/2313-7053-2021-57-4-97-105</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Hasanova DR, Zhitkova JV, Vaskaeva GR. Post-COVID syndrome: A review of pathophysiology, neuropsychiatrie manifestations and treatment perspectives. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2021;13(3):93–98. EDN: YJESZP doi: 10.14412/2074-2711-2021-3-93-98</mixed-citation><mixed-citation xml:lang="ru">Хасанова Д.Р., Житкова Ю.В., Васкаева Г.Р. Постковидный синдром: обзор знаний о патогенезе, нейропсихиатрических проявлениях и перспективах лечения // Неврология, нейропсихиатрия, психосоматика. 2021. Т. 13, № 3. С. 93–98. EDN: YJESZP doi: 10.14412/2074-2711-2021-3-93-98</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Ahmedzhanova LT, Ostroumova TM, Soloha OA. Management of patients with pain syndromes associated with Covid-19. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2021;13(5):96–101. EDN: MAFHCH doi: 10.14412/2074-2711-2021-5-96-101</mixed-citation><mixed-citation xml:lang="ru">Ахмеджанова Л.Т., Остроумова Т.М., Солоха О.А. Ведение пациентов с болевыми синдромами на фоне COVID-19 // Неврология, нейропсихиатрия, психосоматика. 2021. Т. 13, № 5. С. 96–101. EDN: MAFHCH doi: 10.14412/2074-2711-2021-5-96-101</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Hajbullina DH, Maksimov JN. Asthenic post-covid syndrome. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov J Neurol Psychiatry. 2023;23(3):61–69. EDN: XQXTAI doi: 10.17116/jnevro202312303161</mixed-citation><mixed-citation xml:lang="ru">Хайбуллина Д.Х., Максимов Ю.Н. Астенический постковидный синдром // Журнал неврологии и психиатрии им. С.С. Корсакова. 2023. Т. 123, № 3. С. 61–69. EDN: XQXTAI doi: 10.17116/jnevro202312303161</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Naumov KM, Andreeva GO, Bazhenov DA. Differentiated approach to the correction of autonomic disorders in long COVID-19. Russ Military Med Acad Reports. 2021;40(S4):88–91. EDN: PUNVWN</mixed-citation><mixed-citation xml:lang="ru">Наумов К.М., Андреева Г.О., Баженов Д.А. Дифференцированный подход к коррекции вегетативных нарушений при постковидном синдроме // Известия Российской Военно-медицинской академии. 2021. Т. 40, № S4. С. 88–91. EDN: PUNVWN</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Razumov AN, Ponomarenko GN, Badtieva VA, et al. Medical rehabilitation of patients who have suffered COVID-19 in sanatorium-resort organizations. Methodological recommendations. Saint Petersburg; 2021. 30 p. (In Russ.) EDN: AEDCML</mixed-citation><mixed-citation xml:lang="ru">Разумов А.Н., Пономаренко Г.Н., Бадтиева В.А., и др. Медицинская реабилитация пациентов, перенесших COVID-19, в санаторно-курортных организациях. Методические рекомендации. Санкт-Петербург, 2021. 30 с. EDN: AEDCML</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Georgieva E, Ananiev J, Yovchev Y, et al. COVID-19 complications: Oxidative stress, inflammation, and mitochondrial and endothelial dysfunction. Int J Mol Sci. 2023;24(19):14876. EDN: BYFCQR doi: 10.3390/ijms241914876</mixed-citation><mixed-citation xml:lang="ru">Georgieva E., Ananiev J., Yovchev Y., et al. COVID-19 complications: Oxidative stress, inflammation, and mitochondrial and endothelial dysfunction // Int J Mol Sci. 2023. Vol. 24, N 19. P. 14876. EDN: BYFCQR doi: 10.3390/ijms241914876</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Scassellati C, Galoforo AC, Bonvicini C, et al. Ozone: A natural bioactive molecule with antioxidant property as potential new strategy in aging and in neurodegenerative disorders. Ageing Res Rev. 2020;63:101138. EDN: HVHVTG doi: 10.1016/j.arr.2020.101138</mixed-citation><mixed-citation xml:lang="ru">Scassellati C., Galoforo A.C., Bonvicini C., et al. Ozone: A natural bioactive molecule with antioxidant property as potential new strategy in aging and in neurodegenerative disorders // Ageing Res Rev. 2020. Vol. 63. P. 101138. EDN: HVHVTG doi: 10.1016/j.arr.2020.101138</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Frosini M, Contartese A, Zanardi I, et al. Selective ozone concentrations may reduce the ischemic damage after a stroke. Free Radic. Res. 2012;46:612–618. doi: 10.3109/10715762.2012.659247</mixed-citation><mixed-citation xml:lang="ru">Frosini M., Contartese A., Zanardi I., et al. Selective ozone concentrations may reduce the ischemic damage after a stroke // Free Radic. Res. 2012. Vol. 46. P. 612–618. doi: 10.3109/10715762.2012.659247</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Scassellati C, Ciani M, Galoforo AC, et al. Molecular mechanisms in cognitive frailty: Potential therapeutic targets for oxygen-ozone treatment. Mech Ageing Dev. 2020;186:111210. EDN: BIDSKP doi: 10.1016/j.mad.2020.111210</mixed-citation><mixed-citation xml:lang="ru">Scassellati C., Ciani M., Galoforo A.C., et al. Molecular mechanisms in cognitive frailty: Potential therapeutic targets for oxygen-ozone treatment // Mech Ageing Dev. 2020. Vol. 186. P. 111210. EDN: BIDSKP doi: 10.1016/j.mad.2020.111210</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Scassellati C, Galoforo AC, Esposito C, et al. Promising intervention approaches to potentially resolve neuroinflammation and steroid hormones alterations in Alzheimer’s disease and its neuropsychiatric symptoms. Aging Dis. 2021;12(5):1337–1357. doi: 10.14336/AD.2021.0122</mixed-citation><mixed-citation xml:lang="ru">Scassellati C., Galoforo A.C., Esposito C., et al. Promising intervention approaches to potentially resolve neuroinflammation and steroid hormones alterations in Alzheimer’s disease and its neuropsychiatric symptoms // Aging Dis. 2021. Vol. 12, N 5. P. 1337–1357. doi: 10.14336/AD.2021.0122</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Shafiee A, Seighali N, Teymouri Athar M, et al. Levels of brain-derived neurotrophic factor (BDNF) among patients with COVID-19: A systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2024;274(5):1137–1152. EDN: CLHGLX doi: 10.1007/s00406-023-01681-z</mixed-citation><mixed-citation xml:lang="ru">Shafiee A., Seighali N., Teymouri Athar M., et al. Levels of brain-derived neurotrophic factor (BDNF) among patients with COVID-19: A systematic review and meta-analysis // Eur Arch Psychiatry Clin Neurosci. 2023. Vol. 274, N 5. P. 1137–1152. EDN: CLHGLX doi: 10.1007/s00406-023-01681-z</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Keifer J. Regulation of AMPAR trafficking in synaptic plasticity by BDNF and the impact of neurodegenerative disease. J Neurosci Res. 2022;100(4):979–991. EDN: NJVIGA doi: 10.1002/jnr.25022</mixed-citation><mixed-citation xml:lang="ru">Keifer J. Regulation of AMPAR trafficking in synaptic plasticity by BDNF and the impact of neurodegenerative disease // J Neurosci Res. 2022. Vol. 100, N 4. P. 979–991. EDN: NJVIGA doi: 10.1002/jnr.25022</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Demir B, Beyazyüz E, Beyazyüz M, et al. Long-lasting cognitive effects of COVID-19: Is there a role of BDNF? Eur Arch Psychiatry Clin Neurosci. 2023;273(6):1339–1347. EDN: MDIAYV doi: 10.1007/s00406-022-01514-5</mixed-citation><mixed-citation xml:lang="ru">Demir B., Beyazyüz E., Beyazyüz M., et al. Long-lasting cognitive effects of COVID-19: Is there a role of BDNF? // Eur Arch Psychiatry Clin Neurosci. 2023. Vol. 273, N 6. P. 1339–1347. EDN: MDIAYV doi: 10.1007/s00406-022-01514-5</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Tanashjan MM, Kuznecova PI, Raskurazhev AA, Zaslavskaja KJ. The structure of post/long covid fatigue syndrome. Prospects for correction. Terapevticheskii arkhiv = Therapeutic archive. 2023;95(5):418–424. EDN: BYFGQA doi: 10.26442/00403660.2023.05.202224</mixed-citation><mixed-citation xml:lang="ru">Танашян М.М., Кузнецова П.И., Раскуражев А.А., Заславская К.Я. Структура постковидного астенического синдрома. Перспективы коррекции // Терапевтический архив. 2023. Т. 95, № 5. С. 418–424. EDN: BYFGQA doi: 10.26442/00403660.2023.05.202224</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Kopecek M, Stepankova H, Lukavsky J, et al. Montreal Cognitive Assessment (MoCA): Normative data for old and very old czech adults. Applied Neuropsychology: Adult. 2016;24(1):23–29. doi: 10.1080/23279095.2015.1065261</mixed-citation><mixed-citation xml:lang="ru">Kopecek M., Stepankova H., Lukavsky J., et al. Montreal Cognitive Assessment (MoCA): Normative data for old and very old czech adults// Applied Neuropsychology: Adult. 2016. Vol. 24, N 1. P. 23–29. doi: 10.1080/23279095.2015.1065261</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Coppola L, Luongo C, Pastore A, et al. Ozonized autohaemotransfusion could be a potential rapid-acting antidepressant medication in elderly patients. Int J Geriatr Psychiatry. 2010;25(2):208–213. doi: 10.1002/gps.2322</mixed-citation><mixed-citation xml:lang="ru">Coppola L., Luongo C., Pastore A., et al. Ozonized autohaemotransfusion could be a potential rapid-acting antidepressant medication in elderly patients // Int J Geriatr Psychiatry. 2010. Vol. 25, N 2. P. 208–213. doi: 10.1002/gps.2322</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Gumenjuk LN, Ternovaja AI, Parshikova VO, et al. Comparative analysis of the effectiveness of balneotherapy and balneotherapy in combination with magnetic laser therapy at the SPA stage of treatment of patients with true eczema. Medicina. Sociologija. Filosofija. Prikladnye issledovanija. 2023;(3):59–65. EDN: XBZTVE</mixed-citation><mixed-citation xml:lang="ru">Гуменюк Л.Н., Терновая А.И., Паршикова В.О., и др. Эффективность применения озонотерапии у пациентов с постковидным синдромом на этапе санаторно-курортного лечения // Медицина. Социология. Философия. Прикладные исследования. 2023. N 3. С. 59–65. EDN: XBZTVE</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Cvetkova AV, Koneva ES, Kostenko AA, et al. The role of systemic ozone therapy in the rehabilitation of patients after COVID-19. Voprosy kurortologii, fizioterapii i lechebnoi fizicheskoi kultury = Problems of balneology, physiotherapy and exercise therapy. 2022;99(4-2):22–29. EDN: WJOTSV doi: 10.17116/kurort20229904222</mixed-citation><mixed-citation xml:lang="ru">Цветкова А.В., Конева Е.С., Костенко А.А., и др. Роль системной озонотерапии в реабилитации пациентов, перенесших COVID-19 // Вопросы курортологии, физиотерапии и лечебной физической культуры. 2022. Т. 99, № 4-2. С. 22–29. EDN: WJOTSV</mixed-citation></citation-alternatives></ref></ref-list></back></article>
